A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-
A phase 2 trial of Sacituzumab tirumotecan, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Klus Pharma Inc., active and no longer recruiting.
Overview
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) is a phase 2 interventional study registered as NCT05816252 by Klus Pharma Inc., with 356 participants enrolled, started 2023-04-19 and due to reach its primary completion in 2026-06-30. Interventions recorded: SKB264, Pembrolizumab, Carboplatin, Osimertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Osimertinib, Small-cell lung cancer.
- TrialPhase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Osimertinib, Small-cell lung cancer.
- TrialA Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Pembrolizumab, Small-cell lung cancer.
- TrialA Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Pembrolizumab, Small-cell lung cancer.
- TrialA Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Sichuan Kelun-Biotech, Osimertinib, Carboplatin, Pembrolizumab.
- TrialA Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Carboplatin, Small-cell lung cancer.
- TrialPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287
Shares Sacituzumab tirumotecan, Carboplatin, Pembrolizumab, Small-cell lung cancer.
- TrialSKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Carboplatin, Small-cell lung cancer.